deltatrials
Completed NCT00478686

Association of Dihydropyrimidine Dehydrogenase (DPYD) Variants With Toxicity Related to Capecitabine

A Retrospective Analysis of the Association of Dihydropyrimidine Dehydrogenase (DPYD) Variants With Toxicity Related to Capecitabine

Sponsor: M.D. Anderson Cancer Center

Conditions Breast Cancer
Interventions Phlebotomy
Updated 12 times since 2017 Last updated: May 4, 2017 Started: May 23, 2007 Primary completion: May 2, 2017 Completion: May 2, 2017

This observational or N/A phase trial investigates Breast Cancer and is currently completed. M.D. Anderson Cancer Center leads this study, which shows 12 recorded versions since 2007 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

12 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed

  2. Jul 2024 — Sep 2024 [monthly]

    Completed

  3. Dec 2021 — Jul 2024 [monthly]

    Completed

  4. Jan 2021 — Dec 2021 [monthly]

    Completed

  5. Nov 2020 — Jan 2021 [monthly]

    Completed

▶ Show 7 earlier versions

  1. Jun 2018 — Nov 2020 [monthly]

    Completed

  2. May 2018 — Jun 2018 [monthly]

    Completed

  3. Apr 2018 — May 2018 [monthly]

    Completed

    Phase: NA → None

  4. Aug 2017 — Apr 2018 [monthly]

    Completed NA

  5. Jul 2017 — Aug 2017 [monthly]

    Completed NA

    Status: Active Not Recruiting → Completed

  6. Mar 2017 — Jul 2017 [monthly]

    Active Not Recruiting NA

  7. Jan 2017 — Mar 2017 [monthly]

    Active Not Recruiting NA

    First recorded

May 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • M.D. Anderson Cancer Center
  • Myrexis Inc.
Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Houston, United States